CURRICULUM VITAE
`
`Revised October 2016
`
`NAME:
`
`Anthony Michael Sliwinski, M.D.
`
`BIRTHDATE:
`
`5/18/61
`
`BIRTHPLACE:
`
`CITIZENSHIP:
`
`BUSINESS ADDRESS:
`
`TELEPHONE:
`
`LICENSURE:
`
`Washington, D.C.
`
`USA
`
`Virginia Urology Center, P.C.
`9105 Stony Point Drive, Richmond, VA 23235
`14051 St. Francis Blvd., 2nd Flr., Ste. 2001, Midlothian, VA 23114
`
`Office: 330-9105
`
`Virginia 0101-043462
`DEA BS2660834
`
`CERTIFICATION:
`
`American Board of Urology, 2/93; Recertified 10/2010
`
`EDUCATION:
`
`University of Virginia
`Charlottesville, VA
`B.A. Chemistry
`Georgetown University School of Medicine
`Washington, D.C.
`M.D.
`Medical College of Virginia
`Richmond, VA
`7/1986-6/1987
`Internship in Surgery
`Junior Assistant Resident in Surgery 7/1987-6/1988
`Assistant Resident in Urology
`7/1988-6/1989
`Senior Assistant Resident in Urology 7/1989-6/1990
`Chief Resident in Urology
`7/1990-6/1991
`
`1979-1982
`
`8/1982-6/1986
`
`EMPLOYMENT HISTORY:
`
`McGuire Clinic, July 1991-1994
`Urologist--Virginia Urology, August 1994 to present
`
`HOSPITAL APPOINTMENTS:
`
`CJW Medical Center, Richmond, VA (Chippenham & JohnstonWillis)
`Henrico Doctors Hospital, Richmond, VA (Forest, Parham & Retreat)
`Memorial Regional Medical Center, Mechanicsville, VA
`St. Francis Medical Center
`St. Mary's Hospital, Richmond, VA
`
`Sheltering Arms Hospital, Richmond, VA
`Urosurgical Center of Richmond, Richmond, VA
`
`DRL - EXHIBIT 1005
`
`

`

`American Urological Association
`Richmond Academy of Medicine
`Medical Society of Virginia
`Society of Urologic Prosthetic Surgeons (SUPS)
`
`Impotence: Geddings D., Osbon Foundation
`Prostate Cancer: Hanover County Chapter of American Cancer Society
`Urology: BLAB TV, 60 Minutes
`Management of BPH: Southside Regional Medical Center, CME
`Management of BPH: Good Samaritan Hospital Grand Rounds, CME
`Management of Benign Prostatic Hyperplasia: A Urologist's Perspective, Medical
`Update, The Washington Urologic Society
`New Developments in Erectile Dysfunction: Virginia Academy of Family Practice 50th
`Annual Mtg., Virginia Beach Convention Center
`Incontinence: BLAB TV, 60 min.
`Alpha Blockade International Conference on Impotence, Puerto Rico
`Men’s Health Issues: BLAB TV w/John Goodman; 60 min.
`Overactive Bladder, Grand Rounds Presentation: Mary Washington Hospital
`Overactive Bladder, Grand Rounds Presentation: MCV Dept. of OB/GYN
`Overactive Bladder, Grand Rounds Presentation: Ohio State University School of
`Medicine
`Alternative Medicine in Treatment of Overactive Bladder and Irritable Bowel Syndrome:
`SUNA National Conference on Pelvic Floor Disorders, Chicago, IL
`NUTS to LUTS: SUNA National Conference on Pelvic Floor Disorders, Chicago, IL
`Alternative Medicine in Treatment of Overactive Bladder and Irritable Bowel Syndrome:
`Urologic Nurses Association Seminar, MCV, Richmond, VA
`Topic: Erectile Dysfunction, Urological Update 2004, Virginia Urology Center,
`Richmond, VA
`
`MEMBERSHIPS:
`
`
`
`
`PRESENTATIONS:
`
`5/28/92
`9/8/92
`9/15/92
`2/26/93
`3/17/93
`2/21-23/94
`
`7/98
`
`10/98
`1/99
`7/00
`2/01
`3/01
`10/03
`
`3/04
`
`3/04
`3/04
`
`4/24/04
`
`
`
`RESEARCH: PRINCIPAL INVESTIGATOR EXPERIENCE
`
`Aquinox Pharmaceuticals 2016
`ProtocolAQX-1125-301
`Leadership 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm,
`Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doxes of AQX-1125 Targeting the SHIP1
`Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40 Week Extension
`Periods
`
`Allergan 2016
`Protocol 191622-133
`An Exploratory Study of the Safety and Efficacy of BOTOX for the Treatment of Premature Ejaculation
`
`Auxilium Pharmaceuticals 2014
`Protocol AUX-CC-810
`Phase 4:Long-term Safety, Curvature Deformity Characterization and Immunogenicity over Time in Subjects
`Previously Treated with AA4500 for Peyronie’s Disease in Studies AUX-CC-802, AUX-CC-803, AUX CC 804,
`AND AUX CC 806
`
`
`

`

`Afferent Pharmaceuticals 2013
`Protocol AF219-005
`A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and
`Efficacy of AF-219 in Subjects with Interstitial Cystitis /Bladder Pain Syndrome
`
`Vantia Ltd 2012
`Protocol 483-009
`A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Dose Range Finding Study to Determine the
`Efficacy and Safety of Fedovapagon in Men with Nocturia
`
`Auxilium Pharmaceuticals 2011
`Protocol AUX-CC-802
`Title: A Phase 3, Open-Label Study of the Safety and Effectiveness of AA4500 Administered Twice per Treatment
`Cycle for up To Four Treatment Cycles (2x4) In Men With Peyronie’s Disease
`
`Ferring Pharmaceuticals 2007
`Protocol FE9992026 CS31
`A Multi-Center Extension Study Investigating the Long Term Efficacy and Safety of a Fest-Dissolving (“Melt”)
`Formulation of Desmopressin for the Treatment of Nocturia in Adults
`
`Ferring Pharmaceuticals 2007
`Protocol FE992026 CS29
`A Randomized, Double-Blind, Placebo Controlled, Parallel, Group, Multi-Center Study Investigating the Efficacy
`and Safety of a Fast-Dissolving (“Melt”) Formulation of Desmopressin for the Treatment of Nocturia in Adults
`
`Lilly Research Laboratories 2004
`Protocol: F1J-MC-SBCT
`Effect of Duloxetine on Valsalva Leak point Pressure and Quantitative Rhabdosphincter Electromyography
`Measures in Women with Stress Urinary Incontinence
`
`EDAP TMS 2003
`WIRB Protocol #20052702
`EDAP Ablatherm Integrated Imaging High Intensity Focused Ultrasound (HIFU) indicated for Treatment of Low
`Risk, Localized Prostate Cancer.
`
`Bayer Corporation 2002
`Protocol: 10867
`A Randomized, Double Blind, Parallel Group, Multi-Center Study to Investigate the Time to Onset of Action of 20
`mg of Vardenafil Compared to Placebo in Males with Erectile Dysfunction.
`
`Bayer Corporation 2002
`Protocol 10806
`A Randomized, Double-Blind, Multi-Center, Two-Arm Study to Investigate the Safety and Tolerability of Flexible
`Doses of Vardenafil or Sildenafil Given On Demand in African American, Hispanic, and Caucasian Males with
`Erectile Dysfunction.
`
`Bayer Corporation 2001
`Protocol 100285
`A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, fixed-Dose, Parallel group, Three-Month
`Comparison Study to Investigate the Efficacy and Safety of the Phosphodiesterase Type V Inhibitor BAY 38-9456
`in Males with Erectile Dysfunction Following Radical Prostatectomy
`
`

`

`
`Bayer Corporation 2001
`Protocol 10125
`A Randomised, Double-Blind, Multi-Centre, Fixed Dose, Parallel-Group Twelve Month Study to Investigate the
`Safety and Tolerability of the Phosphodiesterase Type V Inhibitor BAY-38-9456 in the Treatment of Patients with
`Erectile Dysfunction in Comparison with Sildenafil.
`
`TAP Holdings Inc 1999
`Protocol M99-038
`A Phase III, Six-Month, Long-Term, Open-Label, Flexible Dose, Safety Extension Study of Uprima Tablets (2, 3,
`and 4 mg) in the Treatment of Male Erectile Dysfunction
`
`TAP Holdings Inc 1998
`Protocol M98-876
`A Phase III At Home Use Study Evaluating the Efficacy and Safety of Escalating Doses of Apomorphine SL to 2, 4
`and 5 mg in the Treatment of Male Erectile Dysfunction
`
`TAP Holdings Inc 1998
`Protocol M97-682
`A Phase Three Long-Term, Open Label, Flexible Dose, Safety Extension Study of Apomorphine SL Tablets in the
`Treatment of Male Erectile Dysfunction.
`
`TAP Holdings Inc 1997
`Protocol M97-763
`A Phase III Efficacy and Safety Study Comparing Escalating Doses of Apomorphine SL to 5 mg or 6 mg Doses of
`Apomorphine SL or Placebo in the Treatment of Male Erectile Dysfunction
`
`
`1991-94
`Ongoing Phase III Clinical Trial: The PLESS Trial: Long term efficacy of Proscar (Finasteride)
`
`
`1991
`MCV clinical experience with lower genitourinary trauma, 1972-present (paper presented at Mid-Atlantic AUA
`Regional Meeting, September 1990). 2nd prize winner, Virginia Section of American College of Surgeons,
`Trauma Presentations, October 1990 (paper pending publication)
`
`
`1989 (Fall)
`Testicular infarction in association with intra-aortic balloon pump (accepted for publication in Urology)
`
`
`1983 (Spring)
`A protocol for the determination of Antabuse (Disulfuram) in human plasma or serum
`
`
`1982 (Spring)
`The effect of substrate on the activity of several ATPases
`
`
`
`
`